TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$48.87
−6.77%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$51.91
From 52W high−27.62%
Volume2.18M
Market cap$4.69B
P/E (TTM)—
P/S (TTM)7.2x
Div yield—
Key dataNov 5, 2026
Open
$51.91
From 52W high
−27.62%
Volume
2.18M
Market cap
$4.69B
ValuationView details →
P/E (Fwd)
16.9x
EV/EBITDA
−49.3x
P/E (TTM)
—
RSI (14)
40.9
MomentumView details →
1D Return
−6.77%
YTD Return
+31.77%
SummaryUpdated Sep 1, 2026
Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company founded in 2008 and headquartered in San Diego, California. Originally incorporated as Retrophin, Inc., the company rebranded to Travere Therapeutics in November 2020. The company specializes in developing and commercializing therapies for rare diseases, with a particular focus on rare kidney disorders and metabolic conditions. Travere has successfully transitioned from a development-stage company to a commercial-stage biopharmaceutical enterprise, with multiple approved products generating revenue and a robust pipeline of investigational therapies targeting significant unmet medical needs in rare disease populations.
Similar companies
Latest newsMore news →
Travere Therapeutics, Inc. reported a quarterly loss of $0.55 per share, compared with a loss of $0.25 per share expected and earnings of $0.28 per share a year earlier.3d agoTravere Therapeutics, Inc. reported third-quarter 2026 financial results and said FILSPARI net product sales were $200 million for the quarter.3d agoTravere Therapeutics announced that it will report its third-quarter 2026 financial results on November 2, 2026, after U.S. markets close, and host a conference call and webcast at 4:30 p.m. ET.10d ago